Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aurinia Pharmaceuticals stock price, quote, forecast and news

AUPH
CA05156V1022
A1W7D4

Price

4.10
Today +/-
+0
Today %
+0 %
P

Aurinia Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aurinia Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aurinia Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aurinia Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aurinia Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aurinia Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aurinia Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aurinia Pharmaceuticals’s growth potential.

Aurinia Pharmaceuticals Revenue, EBIT and net profit per share

DateAurinia Pharmaceuticals RevenueAurinia Pharmaceuticals EBITAurinia Pharmaceuticals Net Income
2029e504.43 M undefined0 undefined215.9 M undefined
2028e470.05 M undefined250.38 M undefined192.93 M undefined
2027e423.36 M undefined213.8 M undefined172.87 M undefined
2026e356.52 M undefined127.44 M undefined129.1 M undefined
2025e287.95 M undefined65.13 M undefined69.05 M undefined
2024e232.86 M undefined12.85 M undefined10.21 M undefined
2023175.51 M undefined-91.69 M undefined-78.02 M undefined
2022134 M undefined-111.5 M undefined-108.2 M undefined
202145.6 M undefined-180.7 M undefined-181 M undefined
202050.1 M undefined-104.3 M undefined-102.7 M undefined
2019300,000 undefined-90.9 M undefined-88.4 M undefined
2018500,000 undefined-56.4 M undefined-64.1 M undefined
2017400,000 undefined-47.6 M undefined-70.8 M undefined
2016200,000 undefined-24.4 M undefined-23.3 M undefined
2015200,000 undefined-23.9 M undefined-18.6 M undefined
2014300,000 undefined-18.4 M undefined-19.4 M undefined
20131 M undefined-4.1 M undefined-2.7 M undefined
20126.1 M undefined-4.1 M undefined-9.7 M undefined
20111 M undefined-6.6 M undefined-2.5 M undefined
20103.3 M undefined-5.1 M undefined-3.7 M undefined
20092.3 M undefined-9.2 M undefined-7 M undefined
20084.4 M undefined-17.9 M undefined-18.1 M undefined
20072.2 M undefined-33.1 M undefined-31.2 M undefined
20063.6 M undefined-24.4 M undefined-23.5 M undefined
20051.1 M undefined-28.9 M undefined-27.9 M undefined
20041.2 M undefined-20.7 M undefined-20.9 M undefined

Aurinia Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
1111412711324231610000005045134175232287356423470504
----300.00200.00-41.67-85.71-200.00-33.33100.00-50.0050.00-66.67500.00-83.33--------10.00197.7830.6032.5723.7124.0418.8211.117.23
100.00---75.0091.6785.71--100.0050.0050.00100.00100.00-100.00100.00-------97.7895.5292.00------
100031160031223061000000044128161000000
-1-2-2-7-8-1-10-20-28-24-33-17-9-5-6-4-4-18-23-24-47-56-90-104-180-111-9112651272132500
-100.00-200.00-200.00-700.00-200.00-8.33-142.86-2,000.00-2,800.00-800.00-1,650.00-425.00-450.00-166.67-600.00-66.67-400.00-------208.00-400.00-82.84-52.005.1722.6535.6750.3553.19-
-2-2-1-6-70-13-20-27-23-31-18-7-3-2-9-2-19-18-23-70-64-88-102-181-108-781069129172192215
---50.00500.0016.67--53.8535.00-14.8134.78-41.94-61.11-57.14-33.33350.00-77.78850.00-5.2627.78204.35-8.5737.5015.9177.45-40.33-27.78-112.82590.0086.9633.3311.6311.98
0.50.50.50.711.31.41.51.61.72.12.12.42.83.53.66.329.232.235.376.984.893118.5129.4141.9143.24000000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aurinia Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aurinia Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aurinia Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aurinia Pharmaceuticals's financial health and stability.

Assets

Aurinia Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aurinia Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aurinia Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aurinia Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-2-1-6-70-13-20-27-23-31-18-7-5-2-9-2-19-18-23-70-64-88-102-180-108-78
0000001221111100011111112211
0000000000000000-30000000000
00000-13-1423-300021-2110-624-21-6-5
000000321-200-2100051332232944736583
000000000000000000000000000
0000000000000000000000000-10
-1-1-1-5-7-1-4-18-20-21-26-19-9-4-1-6-4-16-17-18-41-51-63-69-157-79-33
0000-1-4-2-10-10000-100000000-7-100
000-72-22-1307198001-100-1009-807-158-103-60-6
000-63-17-1027209001000-9010-707-150-102-60-5
000000000000000000000000000
00-1000040-1-111-144000000000000-10
205163112230150340002064902175424319422124
21416311222414-13311-842064704217542431942212-5
00000000000050000-10400000000
000000000000000000000000000
002226-113-131-315-5-1810-5120-1633125-47188-33-40-137-45
-2.17-2.11-1.51-6.79-8.62-5.81-7.2-20.04-21.06-22.88-27.06-20.21-9.8-4.53-2.59-6.56-4.73-17-17.82-18.74-41.2-51.69-63.69-77.2-159.19-79.82-34.18
000000000000000000000000000

Aurinia Pharmaceuticals stock margins

The Aurinia Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aurinia Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aurinia Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aurinia Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aurinia Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aurinia Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aurinia Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aurinia Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aurinia Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aurinia Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aurinia Pharmaceuticals Margin History

Aurinia Pharmaceuticals Gross marginAurinia Pharmaceuticals Profit marginAurinia Pharmaceuticals EBIT marginAurinia Pharmaceuticals Profit margin
2029e91.94 %0 %42.8 %
2028e91.94 %53.27 %41.04 %
2027e91.94 %50.5 %40.83 %
2026e91.94 %35.75 %36.21 %
2025e91.94 %22.62 %23.98 %
2024e91.94 %5.52 %4.39 %
202391.94 %-52.24 %-44.45 %
202295.82 %-83.21 %-80.75 %
202197.59 %-396.27 %-396.93 %
202091.94 %-208.18 %-204.99 %
201991.94 %-30,300 %-29,466.67 %
201891.94 %-11,280 %-12,820 %
2017100 %-11,900 %-17,700 %
2016100 %-12,200 %-11,650 %
2015100 %-11,950 %-9,300 %
201466.67 %-6,133.33 %-6,466.67 %
2013100 %-410 %-270 %
2012100 %-67.21 %-159.02 %
201190 %-660 %-250 %
2010100 %-154.55 %-112.12 %
200995.65 %-400 %-304.35 %
200845.45 %-406.82 %-411.36 %
200754.55 %-1,504.55 %-1,418.18 %
200683.33 %-677.78 %-652.78 %
200527.27 %-2,627.27 %-2,536.36 %
200425 %-1,725 %-1,741.67 %

Aurinia Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Aurinia Pharmaceuticals earnings per share therefore indicates how much revenue Aurinia Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aurinia Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aurinia Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aurinia Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aurinia Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aurinia Pharmaceuticals Revenue, EBIT and net profit per share

DateAurinia Pharmaceuticals Sales per ShareAurinia Pharmaceuticals EBIT per shareAurinia Pharmaceuticals Earnings per Share
2029e3.53 undefined0 undefined1.51 undefined
2028e3.29 undefined0 undefined1.35 undefined
2027e2.96 undefined0 undefined1.21 undefined
2026e2.49 undefined0 undefined0.9 undefined
2025e2.01 undefined0 undefined0.48 undefined
2024e1.63 undefined0 undefined0.07 undefined
20231.23 undefined-0.64 undefined-0.54 undefined
20220.94 undefined-0.79 undefined-0.76 undefined
20210.35 undefined-1.4 undefined-1.4 undefined
20200.42 undefined-0.88 undefined-0.87 undefined
20190 undefined-0.98 undefined-0.95 undefined
20180.01 undefined-0.67 undefined-0.76 undefined
20170.01 undefined-0.62 undefined-0.92 undefined
20160.01 undefined-0.69 undefined-0.66 undefined
20150.01 undefined-0.74 undefined-0.58 undefined
20140.01 undefined-0.63 undefined-0.66 undefined
20130.16 undefined-0.65 undefined-0.43 undefined
20121.69 undefined-1.14 undefined-2.69 undefined
20110.29 undefined-1.89 undefined-0.71 undefined
20101.18 undefined-1.82 undefined-1.32 undefined
20090.96 undefined-3.83 undefined-2.92 undefined
20082.1 undefined-8.52 undefined-8.62 undefined
20071.05 undefined-15.76 undefined-14.86 undefined
20062.12 undefined-14.35 undefined-13.82 undefined
20050.69 undefined-18.06 undefined-17.44 undefined
20040.8 undefined-13.8 undefined-13.93 undefined

Aurinia Pharmaceuticals business model

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that was founded in Canada in 1993. The company specializes in developing therapy options for autoimmune diseases, particularly the treatment of Lupus Nephritis, a condition where the immune system mistakenly attacks the body's own cells and damages the kidneys. Aurinia specializes in the field of biologic medications, which are based on proteins that naturally occur in the human body. These medications are used to modulate the immune system and "suppress" specific cells that trigger autoimmune diseases. Aurinia's main product is Voclosporin, an orally administered drug specifically developed for the treatment of Lupus Nephritis. Clinical trials have shown promising results, and Voclosporin received approval from the US FDA in 2020. Voclosporin is now successfully used in several countries worldwide. Aurinia also conducts research and development in other areas of autoimmune diseases. Another potential application is the treatment of Vogt-Koyanagi-Harada disease, a rare eye condition also attributed to autoimmune diseases. Aurinia's business model is based on developing new therapies that address the medical needs of patients with autoimmune diseases. The company focuses on close collaboration with medical professionals, patients and their families, as well as regulatory authorities. Aurinia has also formed partnerships with other companies and non-profit organizations to support its research and development and enhance access to its products in different countries. Aurinia's success relies on the extensive experience and expertise of its employees in biotechnological research, development and manufacturing of biologic medications, as well as its close partnerships with world-leading physicians in the field of autoimmune diseases. The company is committed to constantly improving the quality of its products and services to enhance patients' quality of life and effectively treat their disease. Overall, Aurinia Pharmaceuticals is a company dedicated to developing innovative therapies for autoimmune diseases, particularly for the treatment of Lupus Nephritis. The company strives to meet the medical needs of patients, their families, and medical professionals while also improving the entire ecosystem of medical care in this field. Aurinia's goal is to provide patients with better and more effective therapies and treatments to improve their health and well-being. Aurinia Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Aurinia Pharmaceuticals SWOT Analysis

Strengths

Aurinia Pharmaceuticals Inc has a strong scientific and research team dedicated to developing innovative pharmaceutical products.

The company has a robust pipeline of drug candidates targeting multiple therapeutic areas.

Aurinia Pharmaceuticals has secured various partnerships and collaborations to support its drug development and commercialization efforts.

Weaknesses

Aurinia Pharmaceuticals heavily relies on the success of its drug candidates, which makes the company vulnerable to failures in clinical trials or regulatory challenges.

The company might face difficulties in obtaining necessary financing for research, development, and marketing activities.

Aurinia Pharmaceuticals is currently dependent on a limited number of key markets, which could pose risks in terms of market diversification.

Opportunities

The increasing prevalence of various diseases, coupled with growing awareness for effective treatments, presents Aurinia Pharmaceuticals with significant market opportunities.

Expanding into emerging markets could provide the company with additional revenue streams and access to a larger patient population.

Advancements in technology and scientific research offer Aurinia Pharmaceuticals the chance to develop breakthrough therapies and gain a competitive advantage.

Threats

Intense competition within the pharmaceutical industry may impede Aurinia Pharmaceuticals' market share and pricing power.

Changes in healthcare regulations and policies could impact the company's ability to obtain regulatory approvals and reimbursement for its products.

Potential intellectual property disputes and patent expirations pose a threat to Aurinia Pharmaceuticals' ability to protect its innovations and maintain a competitive edge.

Aurinia Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Aurinia Pharmaceuticals shares outstanding

The number of shares was Aurinia Pharmaceuticals in 2023 — This indicates how many shares 143.236 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aurinia Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aurinia Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aurinia Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aurinia Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aurinia Pharmaceuticals Stock splits

In Aurinia Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.14 -0.03  (78.48 %)2024 Q1
12/31/2023-0.17 -0.19  (-14.05 %)2023 Q4
9/30/2023-0.17 -0.09  (47.21 %)2023 Q3
6/30/2023-0.19 -0.08  (57.22 %)2023 Q2
3/31/2023-0.23 -0.18  (20.32 %)2023 Q1
12/31/2022-0.28 -0.18  (35.32 %)2022 Q4
9/30/2022-0.17 -0.06  (65.1 %)2022 Q3
6/30/2022-0.23 -0.25  (-9.75 %)2022 Q2
3/31/2022-0.27 -0.27  (0.92 %)2022 Q1
12/31/2021-0.27 -0.25  (8.73 %)2021 Q4
1
2
3
4

Eulerpool ESG Scorecard© for the Aurinia Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

38/ 100

🌱 Environment

4

👫 Social

70

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
198.74
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
198.74
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees51.899
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aurinia Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
6.67 % Armistice Capital LLC9,536,0003,488,00012/31/2023
5.31 % BlackRock Institutional Trust Company, N.A.7,589,076527,69412/31/2023
4.47 % ILJIN SNT Co., Ltd.6,396,283-787,6153/20/2024
2.78 % New Enterprise Associates (NEA)3,969,834012/31/2023
1.89 % State Street Global Advisors (US)2,704,382104,84712/31/2023
1.64 % Nuveen LLC2,346,584-3,85212/31/2023
1.35 % Goldman Sachs Asset Management, L.P.1,925,963550,78412/31/2023
1.10 % Geode Capital Management, L.L.C.1,569,13681,34212/31/2023
1.04 % The Vanguard Group, Inc.1,483,35426,23012/31/2023
0.99 % Citi Investment Research (US)1,416,834532,88412/31/2023
1
2
3
4
5
...
10

Aurinia Pharmaceuticals Executives and Management Board

Mr. Peter Greenleaf53
Aurinia Pharmaceuticals President, Chief Executive Officer, Director (since 2019)
Compensation 8.84 M
Mr. Matthew Donley54
Aurinia Pharmaceuticals Executive Vice President, Operations and Strategy
Compensation 3.31 M
Mr. Joe Miller49
Aurinia Pharmaceuticals Chief Financial Officer
Compensation 3.29 M
Mr. Stephen Robertson41
Aurinia Pharmaceuticals Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Compensation 3.24 M
Dr. Volker Knappertz58
Aurinia Pharmaceuticals Executive Vice President - Research and Development
Compensation 2.98 M
1
2
3
4

Aurinia Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Catalent Stock
Catalent
SupplierCustomer0,520,790,110,760,680,52
Otsuka Holdings Stock
Otsuka Holdings
SupplierCustomer0,25-0,03-0,120,400,320,19
Lonza Group Stock
Lonza Group
SupplierCustomer0,040,82-0,060,690,570,55
1

Most common questions regarding Aurinia Pharmaceuticals

What values and corporate philosophy does Aurinia Pharmaceuticals represent?

Aurinia Pharmaceuticals Inc represents a commitment to improving the lives of patients with serious diseases. The company is dedicated to discovering, developing, and commercializing innovative therapies. With a focus on autoimmune and inflammatory diseases, Aurinia Pharmaceuticals Inc strives to make a meaningful impact on patients' quality of life. The company values scientific excellence, integrity, collaboration, and patient-centricity. Through its research and development efforts, Aurinia Pharmaceuticals Inc aims to provide effective treatments and improve healthcare outcomes for those in need.

In which countries and regions is Aurinia Pharmaceuticals primarily present?

Aurinia Pharmaceuticals Inc primarily operates in multiple countries and regions worldwide. The company has a global presence, with headquarters located in Victoria, British Columbia, Canada. In addition to its Canadian base, Aurinia Pharmaceuticals Inc also has a strong presence in the United States, particularly in Rockville, Maryland, where it has a subsidiary. Furthermore, the company maintains business operations and partnerships in various international markets, including Europe, Asia, and Latin America. Aurinia Pharmaceuticals Inc's focus on global expansion enables them to reach a broader customer base and collaborate with key stakeholders in the pharmaceutical industry.

What significant milestones has the company Aurinia Pharmaceuticals achieved?

Aurinia Pharmaceuticals Inc, a leading biopharmaceutical company, has achieved several significant milestones. One notable accomplishment includes the successful development and commercialization of voclosporin, a potential treatment for various kidney diseases. In 2021, the company obtained regulatory approval for voclosporin as a therapy for lupus nephritis in the United States and Europe. This breakthrough helps cater to the unmet needs of patients suffering from this debilitating condition. With its innovative research and development efforts, Aurinia Pharmaceuticals Inc continues to contribute to the advancement of medical treatments, improving the lives of patients worldwide.

What is the history and background of the company Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals Inc is a Canadian biopharmaceutical company specialized in the development of therapies for autoimmune diseases. Established in 1993, Aurinia has since focused on innovative treatments, particularly for lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE). Led by a team of experienced scientists and pharmaceutical experts, the company has made significant strides in the field of autoimmune diseases. With a commitment to improving patient outcomes, Aurinia Pharmaceuticals Inc continues to explore and develop potential treatments, harnessing cutting-edge technology and extensive research.

Who are the main competitors of Aurinia Pharmaceuticals in the market?

The main competitors of Aurinia Pharmaceuticals Inc in the market are biopharmaceutical companies such as GlaxoSmithKline plc, AstraZeneca plc, and Johnson & Johnson.

In which industries is Aurinia Pharmaceuticals primarily active?

Aurinia Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing therapies for the treatment of various diseases. The business model of Aurinia Pharmaceuticals Inc revolves around researching, developing, and bringing innovative medications to market. They focus on leveraging their expertise in immunology and nephrology to create solutions that address unmet medical needs, particularly in the field of autoimmune diseases. By partnering with healthcare professionals and collaborating with regulatory authorities, Aurinia Pharmaceuticals Inc aims to improve patient outcomes and quality of life. Through their dedicated efforts, Aurinia Pharmaceuticals Inc aims to make a positive impact in the pharmaceutical industry.

What is the P/E ratio of Aurinia Pharmaceuticals 2024?

The Aurinia Pharmaceuticals P/E ratio is 57.52.

What is the P/S ratio of Aurinia Pharmaceuticals 2024?

The Aurinia Pharmaceuticals P/S ratio is 2.52.

What is the AlleAktien quality score of Aurinia Pharmaceuticals?

The AlleAktien quality score for Aurinia Pharmaceuticals is 6/10.

What is the revenue of Aurinia Pharmaceuticals 2024?

The expected Aurinia Pharmaceuticals revenue is 232.86 M USD.

How high is the profit of Aurinia Pharmaceuticals 2024?

The expected Aurinia Pharmaceuticals profit is 10.21 M USD.

What is the business model of Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for severe and life-threatening diseases. The company was founded in 1993 and is headquartered in Victoria, British Columbia, Canada. Aurinia Pharmaceuticals' core business is the development of medications for the treatment of autoimmune diseases such as lupus nephritis, a severe form of lupus disease that can lead to kidney damage. The company has developed a first medication called voclosporin, which is used for the treatment of lupus nephritis. Voclosporin is a powerful calcineurin inhibitor that is already used in other indications, such as the treatment of dry eye. The medication has been proven effective and safe in clinical trials and therefore has the potential to meet a significant need for treatment options for lupus nephritis patients. In addition to developing medications for autoimmune diseases, Aurinia Pharmaceuticals also operates in other areas. The company has entered into a partnership with Otsuka Pharmaceutical Co. Ltd. to develop a novel class of compounds known as protein kinase C inhibitors. These substances have the potential to treat a variety of diseases, including autoimmune diseases. The company is also involved in the development of medications for the treatment of lipid metabolism disorders and eye diseases. Currently, the company is working on the development of medications for the treatment of lipid metabolism disorders, particularly familial chylomicronemia, a rare genetic disorder that leads to excessive accumulation of fats in the body. The ophthalmology division focuses on the development of medications for the treatment of dry eyes and other eye diseases. In summary, Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for severe and life-threatening diseases. The company is currently involved in the development of medications for a variety of indications, including autoimmune diseases, lipid metabolism disorders, and eye diseases. Aurinia Pharmaceuticals' flagship product is voclosporin, which is used for the treatment of lupus nephritis. The company has also formed partnerships with other companies to explore and develop novel compounds with the potential to treat a variety of diseases.

What is the Aurinia Pharmaceuticals dividend?

Aurinia Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Aurinia Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Aurinia Pharmaceuticals or the company does not pay out a dividend.

What is the Aurinia Pharmaceuticals ISIN?

The ISIN of Aurinia Pharmaceuticals is CA05156V1022.

What is the Aurinia Pharmaceuticals WKN?

The WKN of Aurinia Pharmaceuticals is A1W7D4.

What is the Aurinia Pharmaceuticals ticker?

The ticker of Aurinia Pharmaceuticals is AUPH.

How much dividend does Aurinia Pharmaceuticals pay?

Over the past 12 months, Aurinia Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aurinia Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aurinia Pharmaceuticals?

The current dividend yield of Aurinia Pharmaceuticals is .

When does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aurinia Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aurinia Pharmaceuticals located?

Aurinia Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurinia Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurinia Pharmaceuticals from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Aurinia Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Aurinia Pharmaceuticals in the year 2023?

In the year 2023, Aurinia Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aurinia Pharmaceuticals pay out the dividend?

The dividends of Aurinia Pharmaceuticals are distributed in USD.

All fundamentals about Aurinia Pharmaceuticals

Our stock analysis for Aurinia Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurinia Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.